id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-264287-lq4awi0i	Veerapandiyan, Aravindhan	The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID‐19 pandemic	2020-05-05		.txt	text/plain	1766	107	36	The coronavirus disease 2019 (COVID‐19) pandemic has resulted in the reorganization of health‐care settings affecting clinical care delivery to patients with Duchenne and Becker muscular dystrophy (DBMD) as well as other inherited muscular dystrophies. We address issues surrounding corticosteroid and exon‐skipping treatments, cardiac medications, hydroxychloroquine use, emergency/respiratory care, rehabilitation management, and the conduct of clinical trials. 18 We emphasize that treatment decisions should be individualized, and made jointly between the patient, family, and health-care provider, considering any geographic or institution specific policies and precautions for COVID-19. Comprehensive standard of care for patients with DBMD and other muscular dystrophies includes periodic assessments to monitor pulmonary, cardiac, and bone health, as well as side effects from medications or treatments. 24 Due to the uncertain benefits, and the potential risks to skeletal and cardiac muscle, hydroxychloroquine is not recommended for patients with DBMD. The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID-19 pandemic	./cache/cord-264287-lq4awi0i.txt	./txt/cord-264287-lq4awi0i.txt